Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients by Park, Young-Min et al.
Lack of Association between Glutathione S-Transferase-M1, 
-T1, and -P1 Polymorphisms and Olanzapine-Induced 
Weight Gain in Korean Schizophrenic Patients
ObjectiveaaOxidative stress may be an important pathogenic mechanism in the obesity and 
metabolic syndrome. The aims of this study was to assess the possible association between the 
oxidative stress related Glutathione S-Transferase genes (GST-M1, GST-T1, and GST-P1) 
variants and the olanzapine-induced weight gain in Korean schizophrenic patients.
MethodsaaWe categorized 78 schizophrenic patients into two groups the more than 7% weight 
gain from baseline (weight gain ≥7%) and the less weight gain (weight gain <7%) groups ac-
cording to weight change between before and after long-term olanzapine treatment (440± 
288 days). All participants were genotyped for the GST-M1, GST-T1 and GST-P1 genes. Dif-
ferences in allele frequencies between cohorts with different body weight changes were eval-
uated by a chi-square analysis and Fisher’s exact test. The multifactor dimensionality reduc-
tion (MDR) approach was used to analyze gene-gene interactions.
ResultsaaMean body weight gain was 5.42 kg. There was no difference in the null genotype 
distribution of GST-M1 and -T1 between subjects with body weight gain ≥7% compared to 
subjects with body weight gain <7% (p>0.05). No significant difference in GST-P1 genotype 
and allele frequencies were observed between the groups (p>0.05). MDR analysis did not show 
a significant interaction between the three GST gene variants and susceptibility to weight gain 
(p>0.05).
ConclusionaaThese findings do not support a relationship between the genetic variants of 
three GST genes (GST-M1, -T1 and -P1) and weight gain in Korean schizophrenic patients re-
ceiving olanzapine treatment.   Psychiatry Investig 2010;7:147-152
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Introduction
Weight gain, as an adverse reaction induced by the use of atypical antipsychotics, is well 
recognized and has become a serious problem. Weight gain is a major reason for discontin-
uation or noncompliance with atypical antipsychotics. Obesity and weight gain in adulthood 
have been associated with significant health complications such as type II diabetes, coronary 
heart disease, stroke, gallbladder disease, osteoarthritis, obstructive sleep apnea syndrome, re-
spiratory problems and some types of cancer.
1 Substantial weight gain may also adversely af-
fect self-esteem, social functioning and physical activity.
2 Furthermore, medication-induced 
weight gain has been associated with a lower quality of life,
3,4 and is a leading barrier to con-
tinued compliance with psychiatric medications.
5,6 In particular, the dibenzodiazepine-derived 
drugs, clozapine and olanzapine appear to have the greatest weight gain liability. Olanza-
pine is associated with significant weight gain comparable to that produced by clozapine.
7
The underlying mechanisms by which these medications cause weight gain remain unclear. 
However, there are some pharmacological clues, such as those proposed to involve the hista-
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mine, serotonin (5-HT) and adrenergic receptors.
8 In addition 
to these neurotransmitters, it has been reported that antipsy-
chotic-induced weight gain is associated with a state of height-
ened oxidative stress.
9,10 For example, several studies showed 
the positive correlation between indices of obesity, such as 
body mass index (BMI) and waist/hip ratio and the markers of 
oxidative stress such as reduced erythrocyte glutathione.
11,12 
There also has been much interested in the role of free radi-
cals and oxidative stress in the pathogenesis of metabolic syn-
drome.
11,12 It was reported that the oxidative stress was relat-
ed to administration of antipsychotics, which increases dopa-
mine turnover, and leads to excess production of oxidative me-
tabolites in an animal study.
13 Increased production of oxidative 
metabolites leads to the formation of reactive oxygen species 
(ROS). Furthermore, ROS-induced mitochondrial dysfunc-
tion can lead to disruptions of lipid metabolism, increasing the 
intracellular lipid content.
14
Glutathione-S-transferase (GSTs) are enzymes that have ROS 
detoxification properties.
15 GSTs also belong to a superfamily 
of polymorphic enzymes that catalyze the conjugation reac-
tion between reduced glutathione and a variety of xenobiot-
ics including carcinogens, environmental contamination, anti-
cancer agents, antibiotics, and products of the oxidative pro-
cess.
16,17 The imbalance between ROS and antioxidants is re-
lated to insulin resistance in mice and humans.
14,18 It has been 
proposed that increased oxidative stress also underlies the pa-
thophysiology of metabolic syndrome.
19,20 Therefore, func-
tional polymorphisms of GSTs could be considered to be can-
didate genetic markers for a risk factor of weight gain or me-
tabolic syndrome related to antipsychotic use. 
GSTs can be categorized into four main classes: A, M, P, and 
T. Individuals who are homozygous for the null GST-M1 or 
null GST-T1 allele lack the respective enzyme function.
21,22 
GST-P1 is an important GST isoform. Depending on the GST-
P1 polymorphisms, Ile-to-Val changes in the amino acid se-
quence of the protein may alter the activity of the enzyme. Re-
cently there was the finding that GST-P1 Val variant possesses 
five-fold more enzymatic activity to some metabolites in GST-
P1 Ile/Val or Ile/Ile.
23 Therefore, we hypothesized that the null 
alleles of GST-M1, -T1, and the Ile allele of GST-P1 may in-
crease the formation of ROS and then, the disruptions of lipid 
metabolism, increasing the intracellular lipid content, leading 
to the risk of weight gain. We sought to characterize the genet-
ic polymorphisms in the GST-M1, T1, and -P1 genes in schizo-
phrenic patients with and without weight gain in a genetically 
homogenous Korean population. To date there has been no 
study of antipsychotic-induced weight gain associated with 
GST genes yet. We therefore performed the first study of anti-
psychotic-induced weight gain associated with GST gene vari-
ants. We also investigated whether gene-gene interactions am-
ong GST-M1, -T1, and -P1 gene polymorphisms could be cor-
related with olanzapine-induced weight gain in our sample.
Methods
Subjects
A total of 103 schizophrenic patients were enrolled from 
the three collaborating hospitals of Korea University Hospi-
tal. All subjects were examined by trained psychiatrists using 
the Korean version of the Structured Clinical Interview for 
DSM-IV, leading to a diagnosis based on DSM-IV criteria.
24 
Exclusion criteria included evidence of other psychiatric, medi-
cal, or neurological illness; family history of diabetes or eating 
disorder; and age over 65 or under 18 years. Application of 
these criteria resulted in the exclusion of 25 patients. All the 
subjects were ethnic Koreans, and some findings from these 
subjects have been reported previously.
25-27 Written informed 
consents were obtained, and the study protocol was approved 
by the Ethics Committee of the Korea University Hospital.
Seventy-eight subjects were weighed prior to starting olan-
zapine and again after long-term treatment at least 3 months 
(440±288 days). The dosage was adjusted individually ac-
cording to clinical judgment. We controlled the use of drugs 
other than olanzapine. Medications such as antipsychotics, 
mood stabilizers, and antidepressants were avoided during the 
study, because of their potential effects on weight change. How-
ever, we combined the use of benzodiazepines or anticholin-
ergics as needed. No subject had received olanzapine or clo-
zapine prior to the present study. The mean daily dose of olan-
zapine at the end-point examination was 14.05 mg (standard 
deviation=5.1 mg).
Other clinical variables that were measured in the study were 
gender, age, olanzapine treatment duration and dosages, and 
previous antipsychotics dosages (expressed as chlorpromazine 
equivalents). Changes in body weight and BMI during the tr-
eatment were also calculated.
Genotyping
Genetic polymorphism analyses for the GSTM1 and GSTT1 
genes were determined using the multiplex polymerase chain 
reaction (PCR) with modifications of the previously described 
method.
29 The appropriate fragment of the GST gene for the 
GSTM1 and GSTT1 alleles was amplified with specific prim-
ers from human genomic deoxyribonucleic acid (DNA). The 
following primers were used in the PCR reaction: GSTM1, 
(sense) 5’-GAACTCCCTGAAAAGCTAAAGC-3’ and (an-
tisense) 5’-GTTGG-GCTCAAATATACGGTGG-3’; GSTT1, 
(sense) 5’-TTCCTTACTGGTCCTCACATCTC-3’ and (an-
tisense) 5’-TCACGGGATCATGGCCAGCA-3’. PCR was 
performed in a total volume of 30 L containing 100 μg ge-
nomic DNA, 5 M of each primer, 2.5 mM deoxyribonucleo-
side triphosphates, 1.5 mM MgCl2, 100 mM Tris-HCL, and 1 U 
thermostable Taq DNA polymerase with a GeneAmp PCR 
system 2700 (Applied Biosystems, Foster, CA, USA). The am-
plification conditions were initial denaturation at 94℃ for 5 YMParketal.
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min, followed by 35 cycles of denaturation at 94℃ for 45 sec, 
annealing at 59℃ for 50 sec, extension at 72℃ for 1 min, and 
a final extension step at 72℃ for 10 min. The PCR amplifica-
tion products (GSTM1: 215 bp, GSTT1: 480 bp) were then 
separated electrophoretically on an ethidium bromide-stained 
2% agarose gel.
A PCR-based assay was used to detect the GSTP1 polymor-
phism on exon 5.
30 The primer sequences for GSTP1 exon 5 
were (sense) 5’-GAGGAAACTGAGACCCACTGAG-3’ 
and (antisense) 5’-AGCCCCTTTCTTTGTTCAGCC-3’. A 
typical PCR reaction was performed in a 25 μL volume con-
taining 1× PCR buffer, 3.0 mM MgCl2, 0.25 mM dNTPs, 1.5 
units of Taq polymerase, and 0.3 mM of primers GSTP1 exon 
5. The DNA chains were denatured by incubation at 94℃ for 
5 min, followed by 35 cycles of 94℃ for 30 sec, then 60℃ for 
30 sec, and 72 ℃ for 30 sec, followed by a final extension 
step at 72℃ for 5 min. A 424-bp DNA fragment was ampli-
fied for exon 5 and followed by 3 h of digestion with 4 units of 
BsmAI for exon 5 (New England Biolabs, Beverly, MA, USA). 
The fragments were separated on a 3% agarose gel stained 
with ethidium bromide. The Ile/Ile, Ile/Val and Val/Val geno-
types yielded two bands (292 and 132 bp), four bands (292, 
222, 132 and 70 bp), and three bands (222, 132 and 70 bp), res-
pectively. 
Statistical analyses
 Differences in allele frequencies between groups with dif-
ferent body weight changes were evaluated by a chi-square an-
alysis and Fisher’s exact test. The association of genotype with 
weight gain and change in BMI was tested with Student’s t-
test. All of the analyses were performed using standard soft-
ware (Statistical Package for the Social Sciences for Windows), 
and p values smaller than 0.05 were considered statistically 
significant. The multifactor dimensionality reduction (MDR) 
approach was designed to detect gene-gene interactions in the 
presence or absence of main effects in case-control studies in 
human genetics.
31,32 MDR has been shown to have high power 
for detecting interactions in a wide range of simulated data.
33-35 
MDR has also been used to identify interactions in common 
complex diseases.
36-39 MDR is a non-parametric, model-free ap-
proach, making it a unique tool for identifying interactions. 
MDR categorizes all genetic data into 2 groups, “high risk” 
and “low risk”, by comparing all single loci and all multilocus 
combinations and then categorizing each genotype as either 
“high risk” or “low risk” on the basis of the ratio of cases to con-
trols having that genotype. MDR ultimately selects one genet-
ic model, either single or multilocus, that predicts phenotype 
with the greatest success. To evaluate the predictive ability of 
the model, prediction error was calculated using 10-fold cross-
validation. The result is a set of models, one for each model size 
considered. From these models, a final model is chosen on the 
basis of minimization of prediction error and maximization of 
cross-validation consistency (CVC) (number of times a partic-
ular set of factors is identified across the cross-validation sub-
sets). Statistical significance is determined empirically by per-
muting the case and control labels 1,000 times. The use of per-
mutations to generate p values eliminates the problem of mul-
tiple testing. The MDR analysis was carried out using version 
1.1.0 of the MDR software package (http://www.epistasis.org).
Results
There were no differences in age (45.24±11.24 years vs. 
47.41±11.43 years, t=0.83, p=0.41), sex (male/female, 25/12 
Table 1.GSTsgenotypefrequenciesinsubjectswithweightgain<7%andweightgain≥7%
Genotypes
Weight gain <7% (N=37) 
 N (%)





Wild 18 (48.6) 17 (41.5) χ2=0.41, p=0.52
OR=0.75 (0.31-1.83) Null 19 (51.4) 24 (58.5)
GST-T1
Wild 15 (40.5) 17 (41.5) χ2=0.007, p=0.93 
OR=1.04 (0.42-2.57) Null 22 (59.5) 24 (58.5)
GST-M1/GST-T1
Both wild 07 (18.9) 05 (12.2) χ2=0.76, p=0.69
Either null 19 (51.4) 24 (58.5)
Both null 11 (29.7) 12 (29.3)
GST-P1
Ile/Ile 26 (70.3) 26 (63.4) χ2=0.52, p=0.77
Ile/Val 09 (24.3) 13 (31.7)
Val/Val 02 (5.4)0 02 (4.9)0
GST: glutathione S-transferase, OR: odds ratio, CI: confidence interval150  PsychiatryInvestig2010;7:147-152
GSTsandOlanzapine-InduceWeightGain
vs. 27/14, χ2=0.26, p=0.87), initial body weight (67.07±12.64 
kg vs. 62.65±11.82 kg, t=1.60, p=0.12), initial BMI (24.12± 
3.82 kg/m
2 vs. 22.97±3.56 kg/m
2, t=1.37, p=0.17), or olanzap-
ine dosage (14.55±5.46 mg vs. 13.68±4.57 mg, t=0.76, p=0.49) 
between subjects with body weight gains of ≥7% and <7%.
The distributions of the three GST genotypes in our sample 
are shown in Table 1. All groups were in Hardy-Weinberg 
equilibrium with non-significant χ2 values comparing the ob-
served and expected genotype frequencies of each of the test-
ed polymorphisms. There was no difference in the null geno-
type distribution of GST-M1 and -T1 in subjects with body 
weight gain ≥7% compared to subjects with body weight gain 
<7% (p>0.05)(Table 1). To investigate whether the profile of 
GST-M1/T1 genotypes might be associated with the risk of 
olanzapine-induced weight gain, we examined both genotypes 
in combination. There was no difference in the distribution 
of the null genotypes of both GST-M1 and GST-T1 between 
subjects with body weight gain ≥7% and subjects with body 
weight gain <7%.
The observed frequencies of the GST-P1 Ile/Ile, Ile/Val, 
and Val/Val genotypes were 70.3, 24.3 and 5.4%, respectively, 
in 37 subjects with body weight gain <7%. In 41 subjects with 
body weight gain ≥7%, the corresponding frequencies of the 
GST-P1 genotypes were 63.4, 31.7 and 4.9%, respectively. No 
significant difference in genotype frequency was observed 
between the groups (Table 1). Table 2 shows the results of CVC, 
training accuracy and testing accuracy obtained from MDR 
analysis of the data. None of the models selected by MDR were 
statistically significant. 
Discussion
 The mean gains in weight and BMI after long-term olan-
zapine treatment in our 78 Korean schizophrenic patients were 
5.42 kg and BMI 1.99 kg/m
2, respectively. However, we found 
no evidence of an association between the GST polymor-
phism and olanzapine-induced weight gain in Korean schizo-
phrenic patients. All our subjects were inpatients and had taken 
olanzapine for at least 3 months. Although most of our sub-
jects were chronic schizophrenic patients, they had never taken 
olanzapine or clozapine before participating our study. 
Excessive levels of ROS play causative roles in the devel-
opment of insulin resistance and diabetes.
40,41 Recently, there 
has been much interest in the role of free radicals and oxidative 
stress in the pathogenesis of metabolic syndrome.
11,12 Sagara
42 
found that some of the side effects of antipsychotic drug are 
related to oxidative stress and to the level of ROS that is con-
trolled by antioxidant such as glutathione. Kuzuya et al.
19 re-
ported that there was the association between glutathione per-
oxidase 1 (GPX1) 198Leu variants and central obesity in men. 
They also reported that CT/TT genotypes were associated 
with the higher prevalence of metabolic syndrome in men. Th-
erefore, they speculated that these association suggested that 
a weaker antioxidant defense system or greater oxidative stress 
might be a causative factor for obesity. In addition to GPX1, it 
was reported that defective glutathione peroxidase 3 (GPX3) 
expression in adipose tissue is associated with reduced system-
ic GPX activity and increased oxidative stress in obesity.
20 Lee 
et al.
20 proposed that local ROS accumulation in the adipose 
tissue of obesity could be expanded into systemic oxidative st-
ress by the vicious cycle wherein increasing local ROS accu-
mulation suppresses adipose GPX3 expression. Although there 
was no previous study reporting the association between the 
GSTs and weight gain and we also found no evidence of the as-
sociation between the GST polymorphism of glutathione and 
olanzapine-induced weight gain, it is possible that glutathione 
and its related enzymes are associated with obesity and meta-
bolic complication such as metabolic syndrome. 
This study had several limitations. First, its long-term nature 
made complete control over the use of drugs impossible. There-
fore, we could not exclude the effects of different dosages and 
combining medications (e.g., benzodiazepine and benztro-
pine), although the drugs used (regarding olanzapine dosage) 
did not differ significantly among genotype groups. Further-
more, most patients had received other antipsychotics before 
olanzapine treatment, and hence we could not exclude the ef-
fects of prior medication. Second, the duration of medication 
was not the same for all subjects in our sample. However, we 
do not believe that this would have a significant effect, since 
the duration of olanzapine treatment did not differ between the 
genotype groups and we checked the final body weight at least 
3 months later in all patients. Previous studies have found that 
weight was mainly gained during the first 6-8 weeks of olan-
zapine therapy.
43 It is also reported that there was the associa-
tion between the -759C/T polymorphism of the 5-HT2C recep-
tor gene with early phase (after 4 weeks of treatment) weight 
gain induced by antipsychotic treatment in Korean schizo-
phrenia patients.
44 Third, the long-term nature of this study pre-
vented us from assessing or controlling caloric intake (e.g., ca-
loric count and meal refusals. Fourth, the relatively small sam-
Table 2.Summaryofmultifactordimensionalreductionresults
Model Training accuracy Testing accuracy p-value* CVC†
GST-P1 0.5514 0.4490 0.8281 06/10
GST-M1 and -P1 0.5838 0.4320 0.8281 09/10
GST-M1, T1, and P1 0.5950 0.3816 0.9453 10/10
*1,000-fold permutation test, †cross-validation consistency. GST: glutathione S-transferase, CVC: cross-validation consistencyYMParketal.
   www.psychiatryinvestigation.org  151
ple limits the generalizability of our findings. 
Future studies should employ larger samples and control the 
use of medication. In addition, the possible involvement of as-
yet-uncovered gene(s) that influence susceptibility to olanzap-
ine-induced weight gain should be evaluated, as well as the 
possibility of gene-gene and gene-environment interactions.
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